Correction: Noninvasive in vivo imaging and biologic characterization of thyroid tumors by immunopet targeting of galectin-3 (Cancer Research (2016) 76: (3583-3592) DOI: 10.1158/0008-5472.CAN-15-3046);Noninvasive in vivo imaging and biologic characterization of thyroid tumors by immunoPET targeting of galectin-3

Cancer Research

Volumn 76, Issue 12, 2016, Pages 3583-3592

  D'Alessandria, Calogero ^a   Braesch Andersen, Sten ^b   Bejo, Kristel ^c   Reder, Sybille ^a   Blechert, Birgit ^a   Schwaiger, Markus ^a   Bartolazzi, Armando ^c,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Mabtech AB Research Laboratory   (Sweden)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3; MONOCLONAL ANTIBODY; ZIRCONIUM 89; ZIRCONIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOMA CELL LINE; CELL LABELING; CELL LYSATE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; MACROPHAGE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; THYROID CANCER; THYROID NODULE; THYROID TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; DIAGNOSTIC IMAGING; HUMAN; IMMUNOLOGY; PROCEDURES; RADIOIMMUNOASSAY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GALECTIN 3; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNODETECTION; THYROID NEOPLASMS; ZIRCONIUM;

EID: 84976877631     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-1770     Document Type: Erratum

References (50)

1. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to no palpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 2008;126:226-31.
2. Baloch ZW, Sack MJ, Yu GH, Livolsi VA, Gupta PK. Fine -needle aspiration of thyroid: an institutional experience. Thyroid 1998;8:565-9.
3. Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2012;39:569-80.
4. Traugott AL, Dehdashti F, Trinkaus K, Cohen M, Fialkowski E, Quayle F, et al. Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. World J Surg 2010;34:1247-53.
5. Deandreis D, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, et al. Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid 2012;22:165-72.
6. Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF. The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer 2011;117:4582-94.
7. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the pre-operative evaluation of thyroid nodules. J Clin Oncol 1999;17:3494-502.
8. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. Application of immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-50.
9. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicenter study. Lancet Oncol 2008;9:543-9.
10. Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5152-8.
11. Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 2005;18:541-6.
12. Carpi A, Naccarato AG, Iervasi G, Nicolini A, Bevilacqua G, Viacava P, et al. Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer 2006;95:204-9.
13. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010;176:2067-81.
14. Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001;18:787-92.
15. Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, Akahani S, et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 2003;195:111-9.
16. Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 2001;7:661-8.
17. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR)domain of Bcl-2 family. Cancer Res 1997;57:5272-6.
18. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29-41.
19. Harazono Y, Kho DH, Balan V, Nakajima K, Zhang T, Hogan V, et al. Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget 2014;5:9992-10001.
20. Cecchinelli B, Lavra L, Rinaldo C, Iacovelli S, Gurtner A, Gasbarri A, et al. Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 2006;26:4746-57.
21. Keller S, Angrisano T, Florio E, Pero R, Decaussin-Petrucci M, Troncone G, et al. DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. Oncol Lett 2013;6:86-90.
22. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381:1058-69.
23. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
24. Bartolazzi A, Bellotti C, Sciacchitano S. Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules. Appl Immunohistochem Mol Morphol 2012;20:2-7.
25. Inohara H, Raz A. Functional evidence that cell surface Galectin-3 mediates homotypic cell adhesion. Cancer Res 1995;55:3267-71.
26. Dackiw AP, Ezzat S, Huang P, Liu W, Asa SL. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004;145:5840-6.
27. Pushkarev VM, Starenki DV, Saenko VO, Tronko M, Yamashita S. Effects of Paclitaxel and combination of the drug with radiation therapy in an in vivo model of anaplastic thyroid carcinoma. Exp Oncol 2011;33:24-7.
28. Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, Parangi S. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid 2014;24:1241-50.
29. Gasbarri A, Del Prete F, Girnita L, Martegani MP, Natali PG, Bartolazzi A. CD44 adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. Melan Res 2003;13:325-37.
30. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 2010;5:739-43.
31. Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, et al. p- Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 2010;37:250-9.
32. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68-78.
33. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PAJr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
34. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;25:1555-77.
35. Anderson CJ, Connett JM, Schwarz SW, Rocque PA, Guo LW, Philpott GW, et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992;33:1685-91.
36. Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol 2011;38:675-81.
37. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 1992;51:1293-300.
38. Tolmachev V, Rosik D, Wållberg H, Sjöberg A, Sandström M, Hansson M, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37:613-22.
39. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999;26:693-8.
40. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW. Immunohistochemical expression of Galectin-3 in benign and malignant thyroid lesions. Arch Path Lab Med 2002;126:710-3.
41. Griffith OL, Chiu CG, Gown AM, Jones SJ, Wiseman SM. Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev Anticancer Ther 2008;8:1399-413.
42. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos A, et al. Characterization of thyroid follicular neoplasms in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 2005;12:305-17.
43. Boelaert K, McCabe CJ. Thyroid cancer: finding the malignant thyroid nodule in the haystack. Nat Rev Endocrinol 2011;7:563-4.
44. Bartolazzi A, D'Alessandria C, Parisella MG, Signore A, Del Prete F, Lavra L, et al. Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. PLoS One 2008;3:e3768.
45. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 2008;29:193-207.
46. Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol 2012;9:712-20.
47. Sun GH, De Monner S, Davis MM. Epidemiological and economic trends in inpatient and outpatient thyroidectomy in the United States, 1996-2006. Thyroid 2013;26:727-33.
48. Tufano RP, Noureldine SI, Angelos P. Incidental thyroid nodules and thyroid cancer: considerations before determining management. JAMA Otolaryngol Head Neck Surg 2015;141:566-72.
49. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med 2010;51:401-12.
50. Yeh MW, Bauer AJ, Bernet VA, Ferris RL, Loevner LA, Mandel SJ, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid 2015;25:3-14.